StockData
Altimmune, Inc. logo

Altimmune, Inc. (ALT) stock

ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.39−0.14 (-9.15%)

Close on Nov 18, 2026Market cap $270.38MP/E –Yield –

Altimmune free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Altimmune's free cash flow for the twelve months ending Jun 30, 2026 was -$76.56M. For fiscal 2025 it was -$67.55M. The highest annual figure on record is -$3.30M in fiscal 2015.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.55M–
FY2023Dec 31, 2023-$75.86M–
FY2022Dec 31, 2022-$62.71M–
FY2021Dec 31, 2021-$90.36M–
FY2020Dec 31, 2020-$34.51M–
FY2019Dec 31, 2019-$9.60M–
FY2018Dec 31, 2018-$10.36M–
FY2017Dec 31, 2017-$20.33M–
FY2016Dec 31, 2016-$6.48M–
FY2015Dec 31, 2015-$3.30M–
FY2014Dec 31, 2014-$8.57M–
FY2013Dec 31, 2013-$7.25M–
FY2011Dec 31, 2011-$7.88M–
FY2010Dec 31, 2010-$15.24M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.25M–
Q1 FY2026Mar 31, 2026-$20.96M–
Q4 FY2025Dec 31, 2025-$19.45M–
Q3 FY2025Sep 30, 2025-$11.90M–
Q4 FY2023Dec 31, 2023-$16.53M–
Q3 FY2023Sep 30, 2023-$20.49M–
Q2 FY2023Jun 30, 2023-$19.38M–
Q1 FY2023Mar 31, 2023-$19.46M–
Q4 FY2022Dec 31, 2022-$17.34M–
Q3 FY2022Sep 30, 2022-$15.11M–
Q2 FY2022Jun 30, 2022-$16.72M–
Q1 FY2022Mar 31, 2022-$13.54M–
Q4 FY2021Dec 31, 2021-$22.11M–
Q3 FY2021Sep 30, 2021-$17.85M–
Q2 FY2021Jun 30, 2021-$26.62M–
Q1 FY2021Mar 31, 2021-$23.78M–
Q4 FY2020Dec 31, 2020-$13.39M–
Q3 FY2020Sep 30, 2020-$9.56M–
Q2 FY2020Jun 30, 2020-$7.19M–
Q1 FY2020Mar 31, 2020-$4.37M–
Q4 FY2019Dec 31, 2019-$2.00M–
Q3 FY2019Sep 30, 2019-$2.43M–
Q2 FY2019Jun 30, 2019-$3.06M-1718.0%
Q1 FY2019Mar 31, 2019-$2.11M–
Q4 FY2018Dec 31, 2018-$5.16M–
Q3 FY2018Sep 30, 2018-$1.18M–
Q2 FY2018Jun 30, 2018$189.13K–
Q1 FY2018Mar 31, 2018-$4.21M–
Q4 FY2017Dec 31, 2017-$4.83M–
Q3 FY2017Sep 30, 2017-$4.26M–
Q2 FY2017Jun 30, 2017-$7.85M–
Q1 FY2017Mar 31, 2017-$3.38M–
Q4 FY2016Dec 31, 2016-$1.50M–
Q3 FY2016Sep 30, 2016-$1.99M–

More Altimmune figures

See a number that looks wrong?